MedPath

Financial Navigation Study Among Young Adult Blood Cancer Survivors

Not Applicable
Completed
Conditions
Cancer
Financial Stress
Survivorship
Registration Number
NCT05620979
Lead Sponsor
Tufts Medical Center
Brief Summary

Young adult cancer survivors (18-39y) are at increased risk of financial distress. This study seeks to better understand the financial challenges experienced by these individuals via quantitative serial assessments, study-based financial navigator encounters and an end of study qualitative interview.

Detailed Description

This fully remote, multi-site study will evaluate the role of financial navigators in relieving financial distress in young adults (18-39y) who have completed treatment for blood cancer at least three years ago. Serial Assessments at study entry, 3-months, and 6-months measure financial distress measured using the study's primary outcome measure the Personal Financial Wellness Scale™ (PFW) (see below), hypothesized effect modifiers (emotional distress, self-efficacy, cognitive functioning), as well as care seeking, household finances and insurance characteristics. Randomization will occur following completion of baseline measures (see below for description of study arms). In addition to a formal evaluation of the intervention at 3- and 6-months, an optional interview will occur following the 6-month assessment/navigation intervention period to gain further insight from participants about the acceptability of the intervention. For ethical considerations related to the topic of study, all participants will be provided with the Leukemia \& Lymphoma Society's information specialist hotline.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
130
Inclusion Criteria
  1. Previous diagnosis and treatment of blood cancer (leukemia, lymphoma, myeloma, myelodysplastic syndrome, or myeloproliferative neoplasm)
  2. Current age between 18-39 years old
  3. Blood cancer diagnosis during childhood (0-17 years of age) or young adulthood (18-36 years of age)
  4. At least three years post blood cancer diagnosis
  5. Off treatment for blood cancer or on a long-term regimen with an oral anti-cancer medication with stable disease
  6. Off treatment for a second cancer (non-blood cancer) or on a stable long-term regimen, such as hormone therapy or hormone replacement therapy
  7. Primary residence in United States
  8. Able to understand and read the English language
Exclusion Criteria
  • On parent or guardian's insurance

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Personal Financial Wellness Scale (PFW)6 months

To evaluate the change in financial distress associated with randomization group assignment from baseline to 6-month follow up as measured by the 8-item Personal Financial Wellness Scale (PFW). The PFW scores range from 1-10 where lower scores indicate greater financial distress.

Secondary Outcome Measures
NameTimeMethod
Health-Related Quality of Life (HrQoL) Measures6 months

As part of Aim 1, we will explore whether changes in financial distress (baseline to 6-months) are moderated by emotional distress, self-efficacy, and cognitive functioning, as measured by Patient-Reported Measurement Information System (PROMIS) 4-item short forms for emotions distress (depression and anxiety) and self-efficacy, as well as the 4-item cognitive functioning scale from the Quality of Life in Neurological Disorders (Neuro-Qol) battery. For each of these short forms, high scores connote better functioning.

Trial Locations

Locations (5)

Children's Hospital Los Angeles

🇺🇸

Los Angeles, California, United States

University of Southern California (USC Norris Comprehensive Cancer Center & LA County Hospital)

🇺🇸

Los Angeles, California, United States

Tufts Medical Center

🇺🇸

Boston, Massachusetts, United States

Bon Secours Mercy Health System

🇺🇸

Greenville, South Carolina, United States

MD Anderson

🇺🇸

Houston, Texas, United States

Children's Hospital Los Angeles
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.